Payment overview · 2025
General Payments
$254.29
14 reported records · 9 companies
Healthcare provider profile · identity verified
Shealyn Berry, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GROVE, OK · NPI 1407416548
Verified facts
What the public records show
CMS Open Payments records show Shealyn Berry, CNP received $254.29 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Nurtec Odt.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.41 | 32.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.85 | 11.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.01 | 11.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.19 | 9.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.95 | 9.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.58 | 8.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.28 | 6.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.39 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.63 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.29 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.93 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.93 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.01 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.01 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 80 |
| Gabapentin | Gabapentin | 265 | 79 |
| Omeprazole | Omeprazole | 248 | 83 |
| Lisinopril | Lisinopril | 222 | 77 |
| Metformin Hcl | Metformin Hcl | 201 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 66 |
| Losartan Potassium | Losartan Potassium | 188 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 57 |
| Alendronate Sodium | Alendronate Sodium | 156 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 64 |
| Potassium Chloride | Potassium Chloride | 139 | 49 |
| Trazodone Hcl | Trazodone Hcl | 137 | 43 |
| Furosemide | Furosemide | 135 | 52 |
| Meloxicam | Meloxicam | 120 | 35 |
| Montelukast Sodium | Montelukast Sodium | 116 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 107 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 25 |
| Buspirone Hcl | Buspirone Hcl | 87 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 27 |
| Sertraline Hcl | Sertraline Hcl | 76 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 20 |
| Simvastatin | Simvastatin | 71 | 22 |
| Baclofen | Baclofen | 69 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 22 |
| Atenolol | Atenolol | 68 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 20 |
| Topiramate | Topiramate | 68 | 24 |
| Methylprednisolone | Methylprednisolone | 66 | 59 |
| Ezetimibe | Ezetimibe | 63 | 20 |
| Jardiance | Empagliflozin | 62 | 19 |
| Ozempic | Semaglutide | 61 | 18 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 59 | 16 |
| Tramadol Hcl | Tramadol Hcl | 58 | 16 |
| Eliquis | Apixaban | 56 | 17 |
| Prednisone | Prednisone | 56 | 30 |
| Farxiga | Dapagliflozin Propanediol | 55 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 25 |
| Celecoxib | Celecoxib | 54 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 15 |
| Carvedilol | Carvedilol | 52 | 20 |
| Glipizide | Glipizide | 48 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 12 |
| Allopurinol | Allopurinol | 45 | 17 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 15 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Lorazepam | Lorazepam | 33 | 11 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 15 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Diazepam | Diazepam | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Finasteride | Finasteride | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.29 · 14 records | Amgen Inc. | Dexcom G6 Transmitter, EVENITY, JARDIANCE, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, PROLIA, REPATHA, UZEDY, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error